PMID- 33232923
OWN - NLM
STAT- MEDLINE
DCOM- 20210224
LR  - 20210224
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 133
DP  - 2021 Jan
TI  - Long-term treatment of polysaccharides-based hydrogel microparticles as oral 
      insulin delivery in streptozotocin-induced type 2 diabetic mice.
PG  - 110941
LID - S0753-3322(20)31133-1 [pii]
LID - 10.1016/j.biopha.2020.110941 [doi]
AB  - To develop a more effective and safer drug for the treatment of type 2 diabetes 
      mellitus (T2DM), polysaccharides-based hydrogel microparticles as oral insulin 
      delivery was prepared and explored. This study was aimed to evaluate the 
      antidiabetic effects and hypoglycemic mechanism with long-term 
      administration(four weeks) of oral insulin hydrogel microparticles in type 2 
      diabetic mice on a model of diabetes using a high fat diet combined with 
      streptozotocin. The results revealed that the long-term treatment of oral insulin 
      polysaccharides-based hydrogel microparticles could significantly alleviate the 
      symptoms of polyphagia, polydipsia, polyuria and weight loss in diabetic mice. 
      Also, oral administration of insulin hydrogel microparticles could significantly 
      reduce fasting blood glucose levels, ameliorate insulin resistance and increase 
      insulin sensitivity in the mice with T2DM. The concentration of plasma TG, TC, 
      LDL-C, FFA, BUN, CRE significantly decreased and the levels of HDL-C increased 
      showed that insulin polysaccharides-based hydrogel microparticles were effective 
      in regulating lipid metabolism and prevent diabetic nephropathy complication in 
      diabetic mice. In addition, the supplementation of insulin hydrogel 
      microparticles could significant improve the antioxidant capacity by increasing 
      the level of SOD, CAT and decreasing the level of MDA, GPT, NO, TNF-alpha, and 
      reverse histological deterioration of kidney and pancreas in diabetic mice. The 
      above outcome concluded that insulin polysaccharides-based hydrogel 
      microparticles may exhibit promising anti-diabetic activity and the potential to 
      be a drug candidate for T2DM.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Yang, Yu
AU  - Yang Y
AD  - Department of Biology & Guangdong Provincial Key Laboratory of Marine 
      Biotechnology, Institute of Marine Sciences, College of Science, Shantou 
      University, Shantou, Guangdong 515063, PR China.
FAU - Chen, Shengqin
AU  - Chen S
AD  - Department of Biology & Guangdong Provincial Key Laboratory of Marine 
      Biotechnology, Institute of Marine Sciences, College of Science, Shantou 
      University, Shantou, Guangdong 515063, PR China.
FAU - Liu, Yang
AU  - Liu Y
AD  - Department of Biology & Guangdong Provincial Key Laboratory of Marine 
      Biotechnology, Institute of Marine Sciences, College of Science, Shantou 
      University, Shantou, Guangdong 515063, PR China. Electronic address: 
      liuyanglft@stu.edu.cn.
FAU - Huang, Yingbei
AU  - Huang Y
AD  - Department of Biology & Guangdong Provincial Key Laboratory of Marine 
      Biotechnology, Institute of Marine Sciences, College of Science, Shantou 
      University, Shantou, Guangdong 515063, PR China.
FAU - Cheong, Kit-Leong
AU  - Cheong KL
AD  - Department of Biology & Guangdong Provincial Key Laboratory of Marine 
      Biotechnology, Institute of Marine Sciences, College of Science, Shantou 
      University, Shantou, Guangdong 515063, PR China.
FAU - Teng, Bo
AU  - Teng B
AD  - Department of Biology & Guangdong Provincial Key Laboratory of Marine 
      Biotechnology, Institute of Marine Sciences, College of Science, Shantou 
      University, Shantou, Guangdong 515063, PR China.
FAU - Liu, Wenhua
AU  - Liu W
AD  - Department of Biology & Guangdong Provincial Key Laboratory of Marine 
      Biotechnology, Institute of Marine Sciences, College of Science, Shantou 
      University, Shantou, Guangdong 515063, PR China.
LA  - eng
PT  - Journal Article
DEP - 20201121
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Drug Carriers)
RN  - 0 (Hydrogels)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Lipids)
RN  - 0 (Polysaccharides)
RN  - 5W494URQ81 (Streptozocin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Biomarkers/blood
MH  - Blood Glucose/*drug effects/metabolism
MH  - Diabetes Complications/chemically induced/prevention & control
MH  - Diabetes Mellitus, Experimental/blood/chemically induced/*drug therapy
MH  - Diabetes Mellitus, Type 2/blood/chemically induced/*drug therapy
MH  - Diet, High-Fat
MH  - *Drug Carriers
MH  - Drug Compounding
MH  - Hydrogels
MH  - Hypoglycemic Agents/*administration & dosage/chemistry
MH  - Insulin/*administration & dosage/chemistry
MH  - Insulin Resistance
MH  - Lipids/blood
MH  - Male
MH  - Mice
MH  - Particle Size
MH  - Polysaccharides/*chemistry
MH  - Streptozocin
MH  - Time Factors
OTO - NOTNLM
OT  - Antidiabetic effects
OT  - Hydrogel microparticles
OT  - Hyperglycemia
OT  - Long-term treatment
OT  - Oral insulin delivery
OT  - Type 2 diabetes mice
EDAT- 2020/11/25 06:00
MHDA- 2021/02/25 06:00
CRDT- 2020/11/24 20:12
PHST- 2020/08/17 00:00 [received]
PHST- 2020/10/23 00:00 [revised]
PHST- 2020/10/25 00:00 [accepted]
PHST- 2020/11/25 06:00 [pubmed]
PHST- 2021/02/25 06:00 [medline]
PHST- 2020/11/24 20:12 [entrez]
AID - S0753-3322(20)31133-1 [pii]
AID - 10.1016/j.biopha.2020.110941 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2021 Jan;133:110941. doi: 10.1016/j.biopha.2020.110941. Epub 
      2020 Nov 21.